GLAB.CN
Price:
$1.03
Market Cap:
$77.11M
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Industry
Biotechnology
IPO Date
2021-08-12
Stock Exchange
CNQ
Ticker
GLAB.CN
According to Gemina Laboratories Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -20.60. This represents a change of 104.14% compared to the average of -10.09 of the last 4 quarters.
The mean historical PE Ratio of Gemina Laboratories Ltd. over the last ten years is -10.31. The current -20.60 PE Ratio has changed 19.88% with respect to the historical average. Over the past ten years (40 quarters), GLAB.CN's PE Ratio was at its highest in in the January 2021 quarter at -3.46. The PE Ratio was at its lowest in in the July 2020 quarter at -56.17.
Average
-10.31
Median
-7.41
Minimum
-21.38
Maximum
-5.03
Discovering the peaks and valleys of Gemina Laboratories Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 40.06%
Maximum Annual PE Ratio = -5.03
Minimum Annual Increase = -76.46%
Minimum Annual PE Ratio = -21.38
Year | PE Ratio | Change |
---|---|---|
2024 | -7.78 | 10.35% |
2023 | -7.05 | 40.06% |
2022 | -5.03 | -76.46% |
The current PE Ratio of Gemina Laboratories Ltd. (GLAB.CN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-6.62
5-year avg
-10.31
10-year avg
-10.31
Gemina Laboratories Ltd.’s PE Ratio is greater than EnviroMetal Technologies Inc. (-185.15), less than Glow Lifetech Corp. (-3.44), less than Defence Therapeutics Inc. (-10.40), less than Universal Ibogaine Inc. (-0.44), less than BetterLife Pharma Inc. (-2.83),
Company | PE Ratio | Market cap |
---|---|---|
-185.15 | $1.14M | |
-3.44 | $11.22M | |
-10.40 | $50.35M | |
-0.44 | $6.87M | |
-2.83 | $14.25M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gemina Laboratories Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gemina Laboratories Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Gemina Laboratories Ltd.'s PE Ratio?
How is the PE Ratio calculated for Gemina Laboratories Ltd. (GLAB.CN)?
What is the highest PE Ratio for Gemina Laboratories Ltd. (GLAB.CN)?
What is the 3-year average PE Ratio for Gemina Laboratories Ltd. (GLAB.CN)?
What is the 5-year average PE Ratio for Gemina Laboratories Ltd. (GLAB.CN)?
How does the current PE Ratio for Gemina Laboratories Ltd. (GLAB.CN) compare to its historical average?